Why the study?
Does enalapril reduce urinary microalbumin excretion in normotensive patients with Type 2 diabetes mellitus and microalbuminuria?
Does enalapril reduce urinary microalbumin excretion in normotensive patients with Type 2 diabetes mellitus and microalbuminuria?
Long-term enalapril treatment significantly reduces urinary microalbumin excretion in normotensive Type 2 diabetic patients, independent of blood pressure changes.
Supports enalapril initiation for microalbuminuria in normotensive type 2 diabetes; confirms renoprotection independent of blood pressure effects.
The beneficial effect of long-term treatment with an angiotensin-converting enzyme (ACE) inhibitor on urinary microalbumin excretion (UAE) and renal function was investigated in a 4 year, randomized prospective study in normotensive patients with non-insulin-dependent (Type 2) diabetes mellitus. Sixty-two normotensive patients with Type 2 diabetes mellitus and microalbuminuria but normal renal function were randomized to receive either enalapril 5 mg day-1 or no treatment. In the enalapril-treated patients, UAE was reduced from 115.4 +/- 80.1 to 95.6 +/- 61.7 mg 24 h-1 after 12 months (p < 0.05) and to 75.3 +/- 44.8 mg 24 h-1 after 48 months (p < 0.001). In the untreated group, UAE increased slowly from 93.9 +/- 69.9 to 150.0 +/- 144.5 mg 24 h-1 after 48 months. No changes in creatinine clearance, blood pressure or HbA1C were seen in either group during the 4-year period. In normotensive Type 2 diabetic patients with early stage of diabetic microalbuminuria. This effect is long-lasting and probably independent of the antihypertensive action of the drug.
No takes yet. Share an insight, caveat, or question.
Sano et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: